Mucosal vaccine using cationic nanogel

US8961983B2 · kind B2 · utility

Assignee

• National University Corporation Tokyo Medical and Dental University · JP

Inventors

• Kazunari Akiyoshi · Kyoto, JP
• Hiroshi Kiyono · Tokyo, JP
• Yoshikazu Yuki · Tokyo, JP
• Tomonori Nochi · Chapel Hill, US

Key dates

• Filing date: Sep 5, 2014
• Grant date: Feb 24, 2015
• Expiry date: Sep 5, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/6087
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A mucosal vaccine for the prevention or treatment of microbial infections is described that is capable of inducing vaccine antigen-specific immune responses in an organism without the addition of a mucosal adjuvant. The mucosal vaccine comprises a composite of a nanogel comprising a hydrophilic polysaccharide having a cationic functional group and a hydrophobic cholesterol added thereto as a side chain and a vaccine antigen. The vaccine is administered via a mucosal route.